ITCI vs. JAZZ, ASND, BPMC, CERE, CYTK, VKTX, LEGN, IONS, OGN, and ELAN
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Cerevel Therapeutics (CERE), Cytokinetics (CYTK), Viking Therapeutics (VKTX), Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical preparations" industry.
Intra-Cellular Therapies (NASDAQ:ITCI) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Jazz Pharmaceuticals received 593 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 80.54% of users gave Jazz Pharmaceuticals an outperform vote while only 67.38% of users gave Intra-Cellular Therapies an outperform vote.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Intra-Cellular Therapies' net margin of -21.57%. Jazz Pharmaceuticals' return on equity of 27.86% beat Intra-Cellular Therapies' return on equity.
Intra-Cellular Therapies currently has a consensus target price of $90.17, indicating a potential upside of 38.72%. Jazz Pharmaceuticals has a consensus target price of $192.75, indicating a potential upside of 76.85%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Intra-Cellular Therapies.
In the previous week, Intra-Cellular Therapies had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 8 mentions for Intra-Cellular Therapies and 6 mentions for Jazz Pharmaceuticals. Intra-Cellular Therapies' average media sentiment score of 1.15 beat Jazz Pharmaceuticals' score of 0.77 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.
92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 3.4% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Jazz Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Intra-Cellular Therapies has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats Intra-Cellular Therapies on 12 of the 18 factors compared between the two stocks.
Get Intra-Cellular Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intra-Cellular Therapies Competitors List
Related Companies and Tools
